{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T04:06:40Z","timestamp":1744344400702,"version":"3.40.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s00120-025-02523-7","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T13:38:43Z","timestamp":1740058723000},"page":"380-386","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Wissenswertes zur medikament\u00f6sen Osteoprotektion in der Uroonkologie","Things worth knowing about drug-based osteoprotection in uro-oncology"],"prefix":"10.1007","volume":"64","author":[{"given":"Christian","family":"Thomas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Baunacke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"key":"2523_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/dj4030028","volume":"4","author":"C Thomas","year":"2016","unstructured":"Thomas\u00a0C, Bartsch\u00a0G, Walter\u00a0C et\u00a0al (2016) Advantages and disadvantages of bone protective agents in metastatic prostate cancer: Lessons learned. Dent\u00a0J 4:1\u20137","journal-title":"Dent J"},{"key":"2523_CR2","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.bone.2010.09.008","volume":"48","author":"E Woodward","year":"2011","unstructured":"Woodward\u00a0E, Jagdev\u00a0S, McParland\u00a0L et\u00a0al (2011) Skeletal complications and survival in renal cancer patients with bone metastases. Bone 48:160\u2013166","journal-title":"Bone"},{"key":"2523_CR3","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1634\/theoncologist.2015-0327","volume":"21","author":"J Mc Dougall","year":"2016","unstructured":"Mc Dougall\u00a0J, Bansal\u00a0A, Goulart\u00a0B et\u00a0al (2016) The clinical and economic impacts of skeletal-related events among medicare enrolees with prostate cancer metastatic to the bone. Oncologist 21:320\u2013326","journal-title":"Oncologist"},{"key":"2523_CR4","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/S1548-5315(12)70101-8","volume":"8","author":"M Hagiwara","year":"2011","unstructured":"Hagiwara\u00a0M, Oglesby\u00a0A, Chung\u00a0K et\u00a0al (2011) The impact of bone metastases and seketal-related events on healthcare costs in prostate cancer patients receiving hormonal therapy. Community Oncol 8:508\u2013515","journal-title":"Community Oncol"},{"key":"2523_CR5","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","volume":"94","author":"F Saad","year":"2002","unstructured":"Saad\u00a0F, Gleason\u00a0DM, Murray\u00a0R et\u00a0al (2002) A randomized, placebo-controlled trial fo zoledronic acid in patients with hormone-refractory metastatic prostate cancer. J\u00a0Natl Cancer Inst 94:1458\u20131468","journal-title":"J Natl Cancer Inst"},{"unstructured":"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zometa","key":"2523_CR6"},{"key":"2523_CR7","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi\u00a0K, Carducci\u00a0M, Smith\u00a0M et\u00a0al (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a\u00a0randomised, double-blind study. Lancet 377:813\u2013822","journal-title":"Lancet"},{"unstructured":"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xgeva","key":"2523_CR8"},{"key":"2523_CR9","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1200\/JCO.2013.51.6500","volume":"32","author":"MR Smith","year":"2014","unstructured":"Smith\u00a0MR, Halabi\u00a0S, Ryan\u00a0CJ et\u00a0al (2014) Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J\u00a0Clin Oncol 32:1143\u20131150","journal-title":"J Clin Oncol"},{"key":"2523_CR10","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.maturitas.2010.11.003","volume":"68","author":"RA Adler","year":"2019","unstructured":"Adler\u00a0RA (2019) Management of osteoporosis in men on androgen deprivation therapy. Maturitas 68:143\u2013147","journal-title":"Maturitas"},{"key":"2523_CR11","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1056\/NEJMoa0809003","volume":"361","author":"MR Smith","year":"2009","unstructured":"Smith\u00a0MR, Egerdie\u00a0B, Hern\u00e1ndez Toriz\u00a0N et\u00a0al (2009) Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N\u00a0Engl J Med 361:745\u2013755","journal-title":"N Engl J Med"},{"unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/overview\/aclasta-epar-summary-public_en.pdf","key":"2523_CR12"},{"key":"2523_CR13","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","volume":"378","author":"MR Smith","year":"2018","unstructured":"Smith\u00a0MR, Saad\u00a0F, Chowdhury\u00a0S et\u00a0al (2018) Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. N\u00a0Engl J Med 378:1408\u20131418","journal-title":"N Engl J Med"},{"key":"2523_CR14","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s10147-010-0074-5","volume":"15","author":"MS Zaghloul","year":"2010","unstructured":"Zaghloul\u00a0MS, Boutrus\u00a0R, El-Hossieny\u00a0H et\u00a0al (2010) A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int J Clin Oncol 15:382\u2013389","journal-title":"Int J Clin Oncol"},{"unstructured":"https:\/\/www.leitlinienprogramm-onkologie.de\/fileadmin\/user_upload\/Downloads\/Leitlinien\/Nierenzellkarzinom\/Version_5\/LL_Nierenzellkarzinom_Langversion_5.0.pdf","key":"2523_CR15"},{"unstructured":"https:\/\/www.leitlinienprogramm-onkologie.de\/fileadmin\/user_upload\/Downloads\/Leitlinien\/Blasenkarzinom\/LL_Harnblasenkarzinom_Langversion_2.01.pdf","key":"2523_CR16"},{"key":"2523_CR17","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","volume":"29","author":"DH Henry","year":"2011","unstructured":"Henry\u00a0DH, Costa\u00a0L, Goldwasser\u00a0F et\u00a0al (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J\u00a0Clin Oncol 29:1125\u20131132","journal-title":"J Clin Oncol"},{"key":"2523_CR18","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","volume":"21","author":"LS Rosen","year":"2003","unstructured":"Rosen\u00a0LS, Gordon\u00a0D, Tchekmedyian\u00a0S et\u00a0al (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a\u00a0phase\u00a0III, double-blind, randomized trial\u2014the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J\u00a0Clin Oncol 21:3150\u20133157","journal-title":"J Clin Oncol"},{"key":"2523_CR19","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1200\/JCO.19.01186","volume":"37","author":"N Yarom","year":"2019","unstructured":"Yarom\u00a0N, Shapiro\u00a0CL, Peterson\u00a0DE et\u00a0al (2019) Medication-Related Osteonecrosis of the Jaw: MASCC\/ISOO\/ASCO Clinical Practice Guideline. J\u00a0Clin Oncol 37:2270\u20132290","journal-title":"J Clin Oncol"},{"key":"2523_CR20","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/j.1600-0714.2011.01091.x","volume":"41","author":"P Vescovi","year":"2012","unstructured":"Vescovi\u00a0P, Merigo\u00a0E, Meleti\u00a0M et\u00a0al (2012) Bisphosphonates-related osteonecrosis of the jaws: a\u00a0concise review of the literature and a\u00a0report of a\u00a0single-centre experience with 151 patients. J\u00a0Oral Pathol Med 41:214\u2013221","journal-title":"J Oral Pathol Med"},{"key":"2523_CR21","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00520-015-2904-5","volume":"24","author":"AT Stopeck","year":"2016","unstructured":"Stopeck\u00a0AT, Fizazi\u00a0K, Body\u00a0JJ et\u00a0al (2016) Safety of long-term denosumab therapy: results from the open label extension phase of two phase\u00a03\u00a0studies in patients with metastatic breast and prostate cancer. Support Care Cancer 24:447\u2013455","journal-title":"Support Care Cancer"},{"unstructured":"https:\/\/www.onkosupport.de\/asors\/content\/e4126\/e1743\/e1861\/e1862\/e4628\/LaufzettelAGSMOFarbefinal.pdf","key":"2523_CR22"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-025-02523-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-025-02523-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-025-02523-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T10:26:59Z","timestamp":1744280819000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-025-02523-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["2523"],"URL":"https:\/\/doi.org\/10.1007\/s00120-025-02523-7","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"type":"print","value":"2731-7064"},{"type":"electronic","value":"2731-7072"}],"subject":[],"published":{"date-parts":[[2025,2,20]]},"assertion":[{"value":"11 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"C.\u00a0Thomas: A.\u00a0Finanzielle Interessen: Vortragshonorare oder Kostenerstattung als passiv Teilnehmende: Amgen, 09\/2022. \u2013 B.\u00a0Nichtfinanzielle Interessen: Direktor der Klinik und Poliklinik f\u00fcr Urologie\/Universit\u00e4tsklinikum Carl Gustav Carus\/Dresden | Mitgliedschaft: Deutsche Gesellschaft f\u00fcr Urologie e.V. M.\u00a0Baunacke: A.\u00a0Finanzielle Interessen: Bristol-Myers Squibb GmbH (Honorar Moderation) | Jansse-Cilag GmbH (Honorar Moderation). \u2013 B.\u00a0Nichtfinanzielle Interessen: Leitender Oberarzt Klinik und Poliklinik f\u00fcr Urologie, Universit\u00e4tsklinikum Dresden | Mitgliedschaften: European Association of Urology | Deutsche Gesellschaft f\u00fcr Urologie e.V. | Arbeitskreis Versorgungsforschung, Qualit\u00e4t und \u00d6konomie der Deutschen Gesellschaft f\u00fcr Urologie e.V. | S\u00e4chsische Gesellschaft f\u00fcr Urologie e.V. | Soci\u00e9t\u00e9 Internationale d\u2019Urologie","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}